Australian company Telix has announced that the first patient has been dosed in a Phase 1 study of its investigational targeted radiation therapy, TLX250, combined with Merck's DNA-dependent protein kinase inhibitor candidate, peposertib. …
First patient dosed in study of Telix's TLX250 with Merck's peposertib
July 19, 2023 Australian Biotech
Latest Video
New Stories
-
Australian researchers solve decades-long mystery on Parkinson’s disease
March 14, 2025 - - Australian Biotech -
Kosi climbers about to embark on day one of 2025 challenge
March 14, 2025 - - Latest News -
Astellas cancer therapy approved for new indication in earlier prostate cancer
March 14, 2025 - - Latest News -
World-first study identifies 'Goldilocks' number of genes to include in pre-pregnancy screening
March 13, 2025 - - Latest News -
Medicines funded by Pharmac tops 50 since last year's budget boost
March 13, 2025 - - Latest News -
Australia is not alone in using rebate payments, but there are some differences
March 13, 2025 - - Latest News -
Australian company confirms the location of key clinical trial
March 13, 2025 - - Australian Biotech